Orvosi hetilap · 2006
[Treatment of nephrotic syndrome in the adult].
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gero László
Аннотация
Approximately two-third of the cases of the adult nephrotic syndrome is caused by a primary glomerular disease, while the remaining one-third is caused by diabetes mellitus, autoimmune diseases, or amyloidosis. There are two different therapies to treat the syndrome: a general and a special treatment. The general treatment includes administering an appropriate diet (reduced intake of proteins and salt), use of diuretics and lipid-lowering drugs (primarily statins) and initiation of anticoagulant treatment, if required. It is generally necessary to administer angiotensin-convertase-enzyme inhibitors and angiotensin receptor blockers as well as initiate a symptomatic treatment to mitigate the loss of special binding-proteins. The special treatment involves the administration of immunosuppressive and cytostatic drugs. This therapy can be initiated only after the evaluation of renal histology and the overall risk status of the patient. Steroids are still the basic immunosuppressive drugs. Their use can be supplemented with other immunosuppressive or cytostatic treatment. In therapy resistant cases, however, new drugs like mycophenolate mofetil or rituximab can also be applied.
Предметные рубрики MeSH
Angiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAnticoagulantsAntineoplastic AgentsDiet, Sodium-RestrictedDietary ProteinsDiureticsGlomerulonephritis, MembranoproliferativeGlomerulonephritis, MembranousGlomerulosclerosis, Focal SegmentalHumansHypolipidemic AgentsImmunosuppressive AgentsMycophenolic AcidNephrosis, LipoidNephrotic SyndromeRituximab